SI3288573T1 - Onkolitični adenovirus, ki kodira protein B7 - Google Patents

Onkolitični adenovirus, ki kodira protein B7

Info

Publication number: SI3288573T1
Authority: SI; Slovenia
Prior art keywords: protein; oncolytic adenovirus; adenovirus encoding; encoding; oncolytic
Prior art date: 2015-04-30

Application number

SI201630679T

Other languages

English (en)

Inventor

Brian Robert Champion

Alice Claire Noel Bromley

Original Assignee

Psioxus Therapeutics Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-30

Filing date

2016-04-29

Publication date

2020-06-30

2015-04-30 Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en

2015-09-24 Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en

2015-12-14 Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en

2016-04-29 Application filed by Psioxus Therapeutics Limited filed Critical Psioxus Therapeutics Limited

2020-06-30 Publication of SI3288573T1 publication Critical patent/SI3288573T1/sl

Links

230000000174 oncolytic effect Effects 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
241000701161 unidentified adenovirus Species 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect

SI201630679T 2015-04-30 2016-04-29 Onkolitični adenovirus, ki kodira protein B7 SI3288573T1 (sl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB1507419.8A GB201507419D0 (en)	2015-04-30	2015-04-30	Virus
GBGB1516936.0A GB201516936D0 (en)	2015-09-24	2015-09-24	Virus
GBGB1522013.0A GB201522013D0 (en)	2015-12-14	2015-12-14	Virus
EP16723043.2A EP3288573B1 (en)	2015-04-30	2016-04-29	Oncolytic adenovirus encoding a b7 protein
PCT/EP2016/059609 WO2016174200A1 (en)	2015-04-30	2016-04-29	Oncolytic adenovirus encoding a b7 protein

Publications (1)

Publication Number	Publication Date
SI3288573T1 true SI3288573T1 (sl)	2020-06-30

Family

ID=56008588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201630679T SI3288573T1 (sl)	2015-04-30	2016-04-29	Onkolitični adenovirus, ki kodira protein B7

Country Status (31)

Country	Link
US (6)	US11000559B2 (sl)
EP (2)	EP3391892A1 (sl)
JP (3)	JP6931229B2 (sl)
KR (3)	KR20240032177A (sl)
CN (2)	CN107690479B (sl)
AU (3)	AU2016256582B2 (sl)
BR (2)	BR122018004815A2 (sl)
CA (1)	CA2984038C (sl)
CL (2)	CL2017002731A1 (sl)
CO (1)	CO2017010831A2 (sl)
CY (1)	CY1122833T1 (sl)
DK (1)	DK3288573T3 (sl)
EA (1)	EA037611B1 (sl)
ES (1)	ES2780366T3 (sl)
HK (1)	HK1249009A1 (sl)
HR (1)	HRP20200439T1 (sl)
HU (1)	HUE048320T2 (sl)
IL (3)	IL284375B (sl)
LT (1)	LT3288573T (sl)
MX (1)	MX2017013684A (sl)
MY (1)	MY183703A (sl)
PE (2)	PE20180241A1 (sl)
PH (1)	PH12017501942A1 (sl)
PL (1)	PL3288573T3 (sl)
PT (1)	PT3288573T (sl)
RS (1)	RS60105B1 (sl)
SA (2)	SA520412637B1 (sl)
SG (3)	SG11201708604TA (sl)
SI (1)	SI3288573T1 (sl)
WO (1)	WO2016174200A1 (sl)
ZA (1)	ZA201801589B (sl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201322851D0 (en)	2013-12-23	2014-02-12	Psioxus Therapeutics Ltd	Method
PT3021859T (pt)	2013-10-25	2018-03-09	Psioxus Therapeutics Ltd	Adenovírus oncolíticos munidos de genes heterólogos
GB201406608D0 (en)	2014-04-12	2014-05-28	Psioxus Therapeutics Ltd	Virus
EP3391892A1 (en)	2015-04-30	2018-10-24	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding a b7 protein
EP3371208A1 (en)	2015-11-02	2018-09-12	Five Prime Therapeutics, Inc.	Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108697745A (zh) *	2015-12-17	2018-10-23	皮斯奥克斯治疗公司	编码抗tcr复合体抗体或片段的b组腺病毒
RS64059B1 (sr) *	2016-03-31	2023-04-28	The European Molecular Biology Laboratory	Protein adenoviralnog omotača izveden iz vehikuluma za isporuku
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
EP3507304B1 (en) *	2016-09-02	2024-04-03	Lentigen Technology, Inc.	Compositions and methods for treating cancer with duocars
CA3037573A1 (en) *	2016-09-27	2018-04-05	Sator Therapeutics LLC	Optimized oncolytic viruses and uses thereof
WO2018083258A1 (en) *	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) *	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) *	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
AU2018215558B2 (en) *	2017-02-03	2023-05-25	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Oncolytic virus therapy
US11789010B2 (en)	2017-04-28	2023-10-17	Five Prime Therapeutics, Inc.	Methods of treatment with CD80 extracellular domain polypeptides
BR112019024656A2 (pt) *	2017-05-25	2020-06-09	Univ Central Florida Res Found Inc	vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
WO2018218240A1 (en) *	2017-05-26	2018-11-29	Epicentrx, Inc.	Recombinant adenoviruses carrying transgenes
CN111246867B (zh)	2017-06-01	2024-04-12	阿卡米斯生物公司	溶瘤病毒和方法
US11573230B2 (en) *	2018-01-26	2023-02-07	Nantcell, Inc.	Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) *	2018-01-31	2018-03-14	Psioxus Therapeutics Ltd	Formulation
US20210040167A1 (en) *	2018-03-05	2021-02-11	The Schepens Eye Research Institute, Inc.	Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
JP7429046B2 (ja) *	2018-03-30	2024-02-07	具紀藤堂	腫脹発生抑制型腫瘍溶解性ウイルス
US20220133823A1 (en) *	2018-09-10	2022-05-05	Genesail Biotech (Shanghai) Co. Ltd.	A modified oncolytic virus, composition and use thereof
EP3725323A1 (en) *	2019-04-17	2020-10-21	Targovax Asa	Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
JP7137696B2 (ja)	2019-05-14	2022-09-14	プロヴェンション・バイオ・インコーポレイテッド	１型糖尿病を予防するための方法および組成物
EP3970754A4 (en) *	2019-05-14	2023-08-02	Oncolys BioPharma, Inc.	METHOD FOR ADMINISTRATION OF AN ONCOLYTIC VIRUS TO TUMOR TISSUE, AND ADMINISTRATION DEVICE
GB201909081D0 (en)	2019-06-25	2019-08-07	Psioxus Therapeutics Ltd	Method
GB202102049D0 (en) *	2021-02-13	2021-03-31	Psioxus Therapeutics Ltd	Viruses
WO2023180527A1 (en) *	2022-03-25	2023-09-28	Universität Zürich	Adenoviral mediated targeting of activated immune cells

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3405241A1 (de) *	1984-02-15	1985-08-29	Bayer Ag, 5090 Leverkusen	1-/4-(benzothia- oder -oxazol-2-ylthio- oder -2-yloxy) phenyl/-1,3,5-triazin-2,4,6-(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
KR920008907B1 (ko) *	1989-11-28	1992-10-10	삼성전자 주식회사	파우어 온/오프시 화면 크기 제어회로
US5358866A (en)	1991-07-03	1994-10-25	The United States Of America As Represented By The Department Of Health And Human Services	Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en)	1993-02-16	1998-12-08	Onyx Pharmaceuticals, Inc.	Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr)	1993-05-18	1995-08-04	Centre Nat Rech Scient	Vecteurs viraux et utilisation en thérapie génique.
CA2144040A1 (fr)	1993-07-13	1995-01-26	Michel Perricaudet	Vecteurs adenoviraux defectifs et utilisation en therapie genique
US5631236A (en)	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en)	1994-01-13	1998-11-03	Calydon	Tissue-specific enhancer active in prostate
US5677170A (en)	1994-03-02	1997-10-14	The Johns Hopkins University	In vitro transposition of artificial transposons
US5877011A (en)	1996-11-20	1999-03-02	Genzyme Corporation	Chimeric adenoviral vectors
CN1242051A (zh)	1996-12-31	2000-01-19	昂尼克斯药物公司	用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en)	1997-02-20	2002-07-16	Johns Hopkins University School Of Medicine	Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US6291214B1 (en)	1998-05-11	2001-09-18	Glaxo Wellcome Inc.	System for generating recombinant viruses
US20020019051A1 (en)	1998-05-27	2002-02-14	Monika Lusky	Chimeric adenoviral vectors
US20030017138A1 (en)	1998-07-08	2003-01-23	Menzo Havenga	Chimeric adenoviruses
CN1110553C (zh)	1998-07-15	2003-06-04	杭州赛狮生物技术开发有限公司	基因工程腺病毒及其用途
AU767975B2 (en) *	1998-09-11	2003-11-27	Genvec, Inc.	Alternatively targeted adenovirus
ES2286902T3 (es)	1998-12-09	2007-12-01	The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services	Vector recombinante que expresa multiples moleculas coestimulantes y aplicaciones de las mismas.
ATE519854T1 (de)	1999-05-17	2011-08-15	Crucell Holland Bv	Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
WO2000073478A2 (en)	1999-06-01	2000-12-07	University Of Washington	Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en)	1999-11-15	2008-07-08	Onyx Pharmaceuticals, Inc.	Oncolytic adenovirus
ES2233600T5 (es) *	2000-01-21	2009-06-22	Biovex Limited	Cepas de virus del herpes.
US7456009B2 (en)	2000-03-07	2008-11-25	Merck & Co., Inc.	Adenovirus formulations
JP2003534806A (ja)	2000-05-31	2003-11-25	ジェンベク、インコーポレイティッド	アデノウイルスベクターのターゲティングの方法および組成物
US7459153B2 (en)	2001-01-04	2008-12-02	Wadell Goeran	Viral vectors for gene therapy
US20050175589A1 (en)	2001-07-13	2005-08-11	Btg International Limited	Anti-neoplastic viral agents
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
EP1327688A1 (en)	2002-01-14	2003-07-16	Vereniging Voor Christelijk Wetenschappelijk Onderwijs	Adenoviruses with enhanced lytic potency
JP2005515784A (ja) *	2002-02-01	2005-06-02	トランジェーヌ、ソシエテ、アノニム	Ｐｏｄに関連した細胞活性を調節するためのアデノウイルスベクター
US20060147420A1 (en)	2004-03-10	2006-07-06	Juan Fueyo	Oncolytic adenovirus armed with therapeutic genes
US7858367B2 (en)	2002-04-30	2010-12-28	Duke University	Viral vectors and methods for producing and using the same
CN1705740B (zh) *	2002-10-15	2013-07-24	佩尔·松内·霍尔姆	具有反向基因表达的腺病毒及其应用
US20040167088A1 (en)	2003-02-25	2004-08-26	Genvec, Inc.	Method of using adenoviral vectors with increased persistence in vivo
WO2004087930A1 (en)	2003-03-28	2004-10-14	Saint Louis University	Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en)	2003-06-03	2005-06-23	Derek Ko	Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
AU2004260044B2 (en)	2003-07-18	2009-04-23	Onyx Pharmaceuticals, Inc.	Subgroup B adenoviral vectors for treating disease
US20050186178A1 (en) *	2003-08-28	2005-08-25	Ennist David L.	Oncolytic adenoviral vectors encoding GM-CSF
WO2005107474A2 (en)	2004-04-30	2005-11-17	Introgen Therapeutics, Inc.	Oncolytic adenovirus armed with therapeutic genes
WO2005118825A2 (en) *	2004-05-26	2005-12-15	Schering Aktiengesellschaft	Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh)	2004-06-07	2008-01-16	成都康弘生物科技有限公司	肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) *	2004-07-22	2006-12-28	Hawkins Lynda K	Addition of transgenes into adenoviral vectors
CN101068933A (zh) *	2004-08-25	2007-11-07	细胞基因***有限公司	用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
JP2008511336A (ja) *	2004-09-01	2008-04-17	アメリカ合衆国	免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
WO2006060314A2 (en)	2004-12-01	2006-06-08	Bayer Schering Pharma Aktiengesellschaft	Generation of replication competent viruses for therapeutic use
CA2620495A1 (en)	2005-08-31	2007-03-08	Genvec, Inc.	Adenoviral vector-based malaria vaccines
DE102005055128B4 (de)	2005-11-15	2015-04-02	Universität Rostock	Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es)	2006-02-01	2009-08-12	Dnatrix Inc.	Adenovirus oncoliticos para el tratamiento del cancer.
WO2008080003A2 (en)	2006-12-22	2008-07-03	Bayer Schering Pharma Aktiengesellschaft	Generation of oncolytic adenoviruses and uses thereof
WO2009143610A1 (en)	2008-05-27	2009-12-03	Oncolytics Biotech Inc.	Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) *	2008-10-23	2009-03-11	浙江理工大学	晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es)	2009-05-06	2013-05-06	Fundació Privada Institut D'investigació Biomèdica De Bellvitge	Adenovirus oncolíticos para el tratamiento del cáncer.
WO2011043719A1 (en) *	2009-10-05	2011-04-14	Ya-Fang Mei	Replicating viral vectors for gene therapy
SG187784A1 (en)	2010-08-16	2013-03-28	Salk Inst For Biological Studi	Adenoviral assembly method
KR20130138245A (ko) *	2010-09-24	2013-12-18	온코스 테라퓨틱스 오와이	종양분해 아데노바이러스 벡터 및 이와 관련된 방법 및 용도
AU2011306845C1 (en)	2010-09-24	2015-05-14	Oncos Therapeutics Oy	Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
JP2015507604A (ja)	2011-11-14	2015-03-12	リジェネレイティブサイエンシーズ，エルエルシー	懸濁粒子送達システムおよび方法
CN102586327B (zh)	2012-01-18	2013-09-11	陕西师范大学	一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
JP2016512199A (ja)	2013-03-05	2016-04-25	ベイラーカレッジオブメディスンＢａｙｌｏｒＣｏｌｌｅｇｅＯｆＭｅｄｉｃｉｎｅ	腫瘍溶解性ウイルス
GB201322851D0 (en)	2013-12-23	2014-02-12	Psioxus Therapeutics Ltd	Method
PT3021859T (pt)	2013-10-25	2018-03-09	Psioxus Therapeutics Ltd	Adenovírus oncolíticos munidos de genes heterólogos
SG10201907841UA (en)	2013-11-22	2019-10-30	Dnatrix Inc	Adenovirus expressing immune cell stimulatory receptor agonist(s)
GB201406608D0 (en) *	2014-04-12	2014-05-28	Psioxus Therapeutics Ltd	Virus
GB201510197D0 (en) *	2014-06-12	2015-07-29	Psioxus Therapeutics Ltd	Method of treating ovarian cancer
GB201503500D0 (en)	2015-03-02	2015-04-15	Ucl Business Plc	Cell
SG11201707541WA (en)	2015-03-17	2017-10-30	Tilt Biotherapeutics Oy	Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
EP3391892A1 (en)	2015-04-30	2018-10-24	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding a b7 protein
CN108697745A (zh)	2015-12-17	2018-10-23	皮斯奥克斯治疗公司	编码抗tcr复合体抗体或片段的b组腺病毒
US20210198689A1 (en)	2016-03-18	2021-07-01	Nant Holdings Ip, Llc	Multimodal Vector for Dendritic Cell Infection
EP3503918B1 (en)	2016-08-29	2020-09-30	Psioxus Therapeutics Limited	Adenovirus armed with bispecific t cell engager (bite)
GB201713765D0 (en)	2017-08-28	2017-10-11	Psioxus Therapeutics Ltd	Modified adenovirus
EP3872180A1 (en)	2016-10-20	2021-09-01	Alpine Immune Sciences, Inc.	Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083257A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding at least three transgenes
CN111246867B (zh) *	2017-06-01	2024-04-12	阿卡米斯生物公司	溶瘤病毒和方法
GB201801614D0 (en)	2018-01-31	2018-03-14	Psioxus Therapeutics Ltd	Formulation

2016
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 KR KR1020247006825A patent/KR20240032177A/ko not_active Application Discontinuation
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active IP Right Grant
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko active Application Filing
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en active Application Filing
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-06-20 HK HK18107929.1A patent/HK1249009A1/zh unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
2020
- 2020-03-17 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active

Also Published As

Publication number	Publication date
KR20240032177A (ko)	2024-03-08
AU2018201446A1 (en)	2018-03-29
CY1122833T1 (el)	2021-05-05
LT3288573T (lt)	2020-03-25
PL3288573T3 (pl)	2020-05-18
US10548929B2 (en)	2020-02-04
PE20180241A1 (es)	2018-01-31
US10322152B2 (en)	2019-06-18
US11000559B2 (en)	2021-05-11
HUE048320T2 (hu)	2020-07-28
AU2016256582B2 (en)	2020-10-29
BR112017023171A2 (pt)	2018-07-17
KR20180022638A (ko)	2018-03-06
SG10201803081TA (en)	2018-06-28
JP2018139586A (ja)	2018-09-13
EA037611B1 (ru)	2021-04-21
EA201791971A1 (ru)	2018-04-30
CL2017002731A1 (es)	2018-06-08
HK1249009A1 (zh)	2018-10-26
US20180140649A1 (en)	2018-05-24
CN107690479B (zh)	2022-02-18
SG11201708604TA (en)	2017-11-29
PT3288573T (pt)	2020-03-25
HRP20200439T1 (hr)	2020-06-12
EP3391892A1 (en)	2018-10-24
CN108396015B (zh)	2022-02-18
JP2021176339A (ja)	2021-11-11
IL284375B (en)	2022-07-01
IL258044B (en)	2021-07-29
DK3288573T3 (da)	2020-03-16
SA520412637B1 (ar)	2022-03-01
IL258044A (en)	2018-05-31
PH12017501942A1 (en)	2018-03-19
ZA201801589B (en)	2019-10-30
RS60105B1 (sr)	2020-05-29
EP3288573A1 (en)	2018-03-07
MY183703A (en)	2021-03-09
CN107690479A (zh)	2018-02-13
CO2017010831A2 (es)	2018-02-28
IL255286B (en)	2021-01-31
ES2780366T3 (es)	2020-08-25
KR102643574B1 (ko)	2024-03-06
EP3288573B1 (en)	2020-02-12
KR20180118249A (ko)	2018-10-30
IL255286A0 (en)	2017-12-31
US20180042973A1 (en)	2018-02-15
AU2020223665A1 (en)	2020-09-10
US20170056458A1 (en)	2017-03-02
CN108396015A (zh)	2018-08-14
US10849945B2 (en)	2020-12-01
US20170266243A1 (en)	2017-09-21
US20190076493A1 (en)	2019-03-14
JP2018514199A (ja)	2018-06-07
AU2016256582A1 (en)	2017-11-16
WO2016174200A1 (en)	2016-11-03
BR122018004815A2 (pt)	2019-09-10
JP6931229B2 (ja)	2021-09-01
AU2018201446B2 (en)	2020-05-28
JP7162929B2 (ja)	2022-10-31
CL2018000587A1 (es)	2018-08-10
SA517390260B1 (ar)	2021-11-10
AU2016256582A8 (en)	2018-01-18
CA2984038A1 (en)	2016-11-03
CA2984038C (en)	2023-01-03
IL284375A (en)	2021-07-29
JP6928380B2 (ja)	2021-09-01
MX2017013684A (es)	2018-08-28
PE20181140A1 (es)	2018-07-17
US20210338753A1 (en)	2021-11-04
SG10201901482XA (en)	2019-03-28
US10124028B2 (en)	2018-11-13

Publication	Publication Date	Title
HK1249009A1 (zh)	2018-10-26	編碼b7蛋白質的溶瘤腺病毒
IL282985B (en)	2022-04-01	Oncolytic virus modifications
IL260027A (en)	2018-07-31	A group b adenovirus that encodes an anti-tcr-complex antibody or particle
ZA201802261B (en)	2022-10-26	Polypeptides
HK1250041A1 (zh)	2018-11-23	多肽
HUE062816T2 (hu)	2023-12-28	Onkolitikus vakciniavírus
GB201713765D0 (en)	2017-10-11	Modified adenovirus
PL3303291T3 (pl)	2020-09-21	Modulatory ROR-gamma
GB201409634D0 (en)	2014-07-16	Intra block copy mode encoding choice
PL3303290T3 (pl)	2020-09-21	Modulatory ROR-gamma
PL3303293T3 (pl)	2020-10-05	Modulatory ROR-gamma
ZA201704366B (en)	2022-09-28	Il-17a-binding polypeptides
HK1250040A1 (zh)	2018-11-23	多肽
PL3319942T3 (pl)	2021-01-11	MODULATORY ROR-GAMMA (RORγ)
IL267267A (en)	2019-08-29	Vibration sensing system with wavelength encoding
EP3239962A4 (en)	2018-05-09	Encoding device
GB201510457D0 (en)	2015-07-29	Optimized multi-view image encoding
GB201614607D0 (en)	2016-10-12	Modified adenovirus
GB201706219D0 (en)	2017-05-31	Modified adenovirus
GB201700663D0 (en)	2017-03-01	Modified adenovirus
GB201516655D0 (en)	2015-11-04	IX sensor
GB201401159D0 (en)	2014-03-12	Adenovirus
GB201403024D0 (en)	2014-04-09	Polypeptides
GB201400215D0 (en)	2014-02-26	Modulators